drugset / Trial / NCT03535363
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
NaSingle-groupOpen-labelTreatment
Summary
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
Timeline
- Start
- 2018-10-26
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 40 mg | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |